Contact Information
38 the FenwayBoston, MA 02215
Phone: 617-536-0220
Fax: 617-536-0657
Email: jjosephson@replikins.com
Website: http://www.replikins.com
Replikins Company Profile
Replikins, Ltd. develops and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases (FluForecastâ„¢) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntopeâ„¢ vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.News from Replikins:
Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
BOSTON, Dec. 11, 2007 — Replikins Ltd. today announced its latest findings regarding the virus replikin count in human H5N1 influenza virus. The company’s software-driven analysis has found that the prevalence of these se…
AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers
BOSTON, Dec. 6, 2007 — A gene related to rapid replication and lethality has been found to be present in, and to contain some identical protein sequences in, tobacco mosaic virus and non-small cell lung cancer. The early detection di…
Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
BOSTON, AUG. 3, 2007 — Replikins LLC has discovered a new group of virus structural peptides within virus proteins, called replikins, which provide virus-specific advance quantitative warnings of rapid replication and the risk…
Indonesia Reports Experiencing Human H5N1 Mortality Increase, as Predicted Last Year by Replikins’ FluForecast(R) Quantitative Virus Analysis
BOSTON, June 8, 2007 — The results published in 2006 by Replikins, Ltd. showed that 2005-2006 FluForecast(R) virus data indicated clearly that 1) the mortality rate of human H5N1 was increasing markedly, and that 2) the first count…
FluForecast(R) Trial in 2006 Predicted High Human H5N1 Mortality in Indonesia
BOSTON, May 9, 2007 — When H5N1 was thought to be quiescent in 2006, in a prospective open trial, FluForecast(R), a software program which measures virus gene proteins, predicted high human mortality H5N1 outbreaks to come2. In add…
Gene Segment Identified in Virulent Human H5N1 Viruses
Key discovery may enable development of vaccines, therapeutics
BOSTON, Jan. 25, 2007 — Viruses whose genomes constantly mutate, such as the H5N1 "bird flu," are driving a race to find relatively unchanging segments of…
Human H5N1 Virus Replikin Count Overtakes That in H5N1 ‘Bird Flu’
BOSTON, Dec. 28, 2006 — A common question asked at current scientific conferences is: "Where did bird flu go?"
The recent decrease in reported H5N1 human cases and bird outbreaks might indicate that the virus has become d…
Rising H5N1 ‘Bird Flu’ High-Virulence Sequences Found By Replikins, Ltd.
BOSTON, Nov. 6, 2006 — Replikins, Ltd. has completed a comprehensive quantitative analysis of H5N1 "bird flu" peptide sequences found in humans infected with H5N1 in the past nine years.
The data, obtained from public s…
Advance Warning of H5N1 Influenza Outbreaks May Be Found in Shrimp Virus Reservoirs
BOSTON, Oct. 25, 2006 — Researchers at Replikins, Ltd.[1] have discovered that the shrimp viruses White Spot Syndrome virus (WSSV) and Taura Syndrome virus (TSV) – global lethal pathogens for shrimp – may be reservoi…
Replikins’ FluForecast Software Pinpoints Change in Deadly Bird Flu Amino Acid Sequence in Humans
Single substitution discovered in current H5N1 was also found to be present in the last two major human pandemics of 1957 (H2N2) and 1968 (H3N2)
BOSTON, June 2, 2006 — WHO and CDC spokespersons have recently announced that no signifi…